---
title: 'Sumitovant + Myovant, Thermo Fisher + Binding Site Group, Astellas & Taysha, Agios, Vaxctye'
type: 'episode'
url: 'https://doc.social/episodes/sumitovant-myovant-thermo-fisher-binding-site-group-astellas-taysha-agios-vaxctye'
show: 'Life Science Today'
show_url: 'https://doc.social/podcasts/life-science-today'
published: '2022-11-02'
audio: 'unavailable — the host retired the file'
---

# Sumitovant + Myovant, Thermo Fisher + Binding Site Group, Astellas & Taysha, Agios, Vaxctye

Billion-dollar acquisitions, troubled waters for some biotech’s, and a prosperous outlook for othersFind out more athttps://LifeScienceTodayPodcast.comStory ReferencesSumitovant + MyovantThermo Fisher + Binding Site GroupAstellas & Tays…

## Summary

Billion-dollar acquisitions, troubled waters for some biotech’s, and a prosperous outlook for others

**Find out more at
**[https://LifeScienceTodayPodcast.com
](https://lifesciencetodaypodcast.com/)
**Story References**
[Sumitovant + Myovant
](https://www.biospace.com/article/weeks-after-rejecting-first-offer-myovant-agrees-to-acquisition-by-sumitovant/?s=79)[Thermo Fisher + Binding Site Group
](https://www.biospace.com/article/releases/thermo-fisher-scientific-to-acquire-the-binding-site-group/?s=79)[Astellas & Taysha
](https://www.biospace.com/article/taysha-gene-therapies-and-astellas-inks-investment-and-licensing-deal/?s=79)[Agios](https://www.biospace.com/article/releases/agios-and-sagard-healthcare-partners-announce-131-8-million-purchase-agreement-for-tibsovo-royalty/?s=79)
[Vaxctye](https://www.biospace.com/article/releases/vaxcyte-announces-closing-of-690-million-public-offering-including-full-exercise-of-underwriters-option-to-purchase-additional-shares/?keywords=vaxcyte)**
**
**About the Show
**Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.